| Schedule of Segment Reporting |
The following table presents segment revenue and significant segment expenses (in thousands) for the three and six months ended June 30, 2026 and 2025: | | | | | | | | | | | | | | | | | | | | | | | | | THREE MONTHS ENDED JUNE 30, | | SIX MONTHS ENDED JUNE 30, | | 2026 | | 2025 | | 2026 | | 2025 | | REVENUE: | | | | | | | | | | | | | | | | | | | | | | | | | Total segment revenue | — | | | 18,168 | | | 367 | | | 229,414 | | | LESS: | | | | | | | | | Rinvatercept program expenses | (4,101) | | | (1,431) | | | (6,751) | | | (2,948) | | | Elritercept program expenses | (14) | | | (15,636) | | | (17) | | | (34,531) | | | Cibotercept program expenses | (267) | | | (4,059) | | | 57 | | | (9,967) | | | Preclinical & development expenses | (6,111) | | | (1,981) | | | (8,117) | | | (3,725) | | | Compensation costs (excluding stock based compensation) | (7,725) | | | (13,842) | | | (15,915) | | | (27,619) | | | Other external costs | (6,874) | | | (11,737) | | | (13,921) | | | (19,533) | | | Other segment items2 | (3,618) | | | (178) | | | (8,121) | | | (13,336) | | | Net income (loss) | (28,710) | | | (30,696) | | | (52,418) | | | 117,755 | |
|
| Schedule of Accrued Compensation and Benefits Costs |
2 Other segment items include other expense, income tax provision, bank fees, depreciation expense, dividend income and stock-based compensation. Accrued compensation and benefits costs as of June 30, 2026 is as follows (in thousands): | | | | | | | RESTRUCTURING LIABILITY | | Balance as of December 31, 2025 | 145 | | | Expenses incurred | — | | | Cash payments | (145) | | | Balance as of June 30, 2026 | — | |
|